Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer
Uro-Oncology
Related content
Uro-Oncology
Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter?
Prostate.
Andrews JR, Ahmed ME, Karnes RJ, Kwon E, Bryce AH
doi: 10.1002/pros.23954.
Overactive BladderUro-Oncology
Detection and Clinical Significance of Circulating Tumor Cells in Patients Undergoing Radical Cystectomy for Urothelial Bladder Cancer
Clin Genitourin Cancer.
Pagliarulo V, Ancona P, Petitti T, Salerno A, Spadavecchia R, Di Stasi S, Cormio L, Maurizio B, Carrieri G, Ditonno P
doi: 10.1016/j.clgc.2016.11.005.
Uro-Oncology
Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer
doi: 10.1016/j.eururo.2018.11.016.
COMMENTED
Uro-Oncology
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
★ 2
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
doi: 10.1016/j.eururo.2020.01.012.
Uro-Oncology
Systemic treatments for high-risk localized prostate cancer
Nat Rev Urol.
Pignot G, Maillet D, Gross E, Barthelemy P, Beauval JB, Constans-Schlurmann F, Loriot Y, Ploussard G, Sargos P, Timsit MO, Vincendeau S, Pasticier G, Borchiellini D
doi: 10.1038/s41585-018-0017-x.
Uro-Oncology
Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens
Prostate.
Ylitalo EB, Thysell E, Thellenberg-Karlsson C, Lundholm M, Widmark A, Bergh A, Josefsson A, Brattsand M, Wikström P
doi: 10.1002/pros.23935.
Uro-Oncology
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
Eur Urol.
Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Dos Reis RB, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A
doi: 10.1016/
Uro-Oncology
Development and initial clinical correlation of a DNA methylation-based blood test for prostate cancer
Prostate.
Carson JJK, Di Lena MA, Berman DM, Siemens DR, Mueller CR
doi: 10.1002/pros.24025.
COMMENTED
Uro-Oncology
Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
doi: 10.1016/j.eururo.2020.01.033.